HonCode

Go Back   HER2 Support Group Forums > her2group
Register Gallery FAQ Members List Calendar Today's Posts

Reply
 
Thread Tools Display Modes
Old 05-28-2015, 06:51 PM   #1
waterdreamer
Senior Member
 
waterdreamer's Avatar
 
Join Date: Jan 2010
Location: Thousand Oaks, California.
Posts: 199
Nighttime Fasting Decreases Breast Cancer Risk

http://www.cancernetwork.com/aacr-20...=1&ts=23042015


Nighttime Fasting Decreases Breast Cancer Risk



April 20, 2015 | AACR 2015 Breast Cancer
By Anna Azolinsky, PhD














Women who spend less time eating each day and an increased amount of hours fasting overnight had a decreased risk of breast cancer, according to the results of a study presented at the American Association for Cancer Research (AACR) Annual Meeting, held April 18 to 22 in Philadelphia. This study was also published in Cancer Epidemiology, Biomarkers & Prevention.


Catherine Marinac, a doctoral candidate in public health at the University of California, San Diego, and colleagues found that for every 3-hour increase in fasting during the night, women had a 4% lower glucose measurement 2 hours after a meal (P < .05) and a non-statistically significant 0.4-unit decrease in hemoglobin A1c (HbA1c). Each 3-hour increase in nighttime fasting was also linked with an approximate 20% reduced odds of elevated HbA1c and a non-significant reduced odds of elevated glucose 2 hours after a meal.


Fasting for longer periods of time overnight significantly improved glucose levels, independently of how much the women ate during the day.


This work suggests that by decreasing the hours spent eating in a 24-hour cycle, women may be able to lower their body’s glycemic control, which may impact tumorigenesis.


“We believe that a regular prolonged, 12 to 14 hour nightly fast could potentially target fasting-responsive pathways related to the risk of type 2 diabetes, cardiovascular disease, and many cancers,” Marinac and study author Ruth E. Patterson, PhD, leader of the cancer prevention program in the Moores UCSD Cancer Center, told Cancer Network. “These diseases account for over 50% of deaths among US adults.”


Previous population studies suggested that poor glucose control—such as in individuals with diabetes or metabolic syndrome—is a risk factor for certain types of cancers, including breast cancer, and that diurnal feeding and fasting cycles influence metabolism. A 2007 meta-analysis showed that women with type 2 diabetes have a 23% higher relative risk of developing breast cancer compared with women who are not diabetic. Currently, researchers hypothesize that higher concentrations of circulating glucose can fuel cancer growth and cancer progression since hyperglycemia, a characteristic of diabetes, is linked to increased risk of breast cancer.


According to the authors, this is one of the first studies to show an association between prolonged nightly fasting and breast cancer risk in a nationally representative sample of women.


Studies in mice have suggested that decreasing the hours spent eating each day and increasing the length of time fasted overnight that aligned with sleep/wake cycles can improve glucose metabolism and potentially reduce the risk of chronic diseases such as cancer.


The researchers analyzed the link between length of nighttime fasting with glycemic control biomarkers and breast cancer risk in a sample of women who took part in the 2009–2010 US National Health and Nutrition Examination Survey. The participants had a median age of 47 years.


“An important aspect of this dietary pattern is that it does not require nutrition education, access to healthy foods, or costs involved in many other dietary recommendations. We believe that this change in the nightly fasting interval is a simple and feasible behavioral target that could lead to increased self-efficacy and stimulate people to make additional healthful lifestyles,” said Patterson.
Patterson added that she and her colleagues have submitted a proposal to test their hypothesis in a randomized controlled trial of 326 overweight or obese postmenopausal women whose usual nightly fasting interval is less than 12 hours. “Our pilot data support the feasibility of this intervention in white women and Latinas,” said the authors. They are continuing to investigate this in other study samples, including the Women’s Healthy Eating and Living Study of breast cancer survivors to test whether a prolonged nightly fast can reduce the risk of breast cancer recurrence and mortality.








__________________
Breastfeeding when diagnosed with Her2+ May 2008
Oct 2008 Double mastectomy 22/28 lymph nodes positive
Decline chemotherapy (decision I regret)
Nov 2009 Mets to lungs and bones.
Dec 2009 Start Taxotere and Herceptin, T1, T3 heal completely and lungs are clear, T2 and first rib have lytic lesions. First rib becomes sclerotic. Considered stable.
May 2011, Onc calls progression and I cross over from comparison arm of clinical trial to TDM-1
Brain scan in Sept 2011 showed small tumor in right cerebellum, did Novalis radiation.


Feb 2013 < 1cm tumor in left frontal lobe. Did Novalis in March and latest scan shows no sign of brain metastasis.
Aug 2013 did 36th round of TDM-1 Due to TDM-1 side effects, shortness of breath, and difficulty getting my balance when getting out of bed, agreed with my oncologist to stop TDM-1.
Took a six week break, bone scan showed small uptake on left first rib. CT showed hypodensities in liver (too small to biopsy) and small nodule in lungs (mediastinal).
Started Navelbine weekly. Did one round with Herceptin.
Skipped next 2 rounds, due to neutropenia. Next chemo 7th Nov - have had 3 Neupogen shots, so WBC should look better... Did not tolerate Navelbine well.
December 2013 scans show no sign of active cancer.
March 2014 - currently only on Herceptin - brain MRI clear, PET/CT two nodules in right lung show uptake
May 2014 - stop Herceptin.
Sept 22, 2014 Brain MRI clear :) PET/CT Progression in lungs.
Sept 2014, Xeloda, Tykerb and Herceptin.
Nov 2014 - Decide to take a break from all treatment.
May 2015 - Brain met radiated with Novalis
July 2015 - Have progression in right lung.
Sept 2015 - Perjeta and Herceptin alone after a 9 month break from all treatment.
Nov 2015 - Thoracentesis 1500ml removed from right lung.
Dec 2015 - Two tiny 1mm brain mets radiated in right cerebellum.
Feb 2016 - Thoracentesis 2200ml drained from right lung
Feb 2016 - Stopped Perjeta and Herceptin and started back on Kadcyla as I had no previous progression on it. After 1 cycle of Kadcyla markers begin to drop. On second cycle add Keytruda.
March 2016 - Thoracentesis 1650ml drained from right lung.
April 2016 – Thoracentesis 1500 ml drained from right lung.
June 2016 – CT scan shows progression in right lung, as well as moderate pleural effusion requiring Thoracentesis.
June 2016 – Decide to stop Keytruda, and will do chemosensitivity test through Rational Therapeutics. Plan to continue on Kadcyla for next two cycles.
July 2016 - Start weekly Abraxane with Herceptin. WBRT with hippocampal sparing, Taking Namenda. 15 sessions over 3 weeks.
Aug - Dec 2016 - 2 infusions of Navelbine, very hard on my body and still dealing with anasarca (generalized edema) 1 infusion of Havalen
My doctor wants to put me on hospice.
Dec 23rd 2016 - I am granted compassionate use of Neratanib.
May 31st 2017 - still on Neratinib, feeling good.
waterdreamer is offline   Reply With Quote
Old 05-30-2015, 06:25 PM   #2
KDR
Senior Member
 
KDR's Avatar
 
Join Date: Aug 2010
Location: New York, New York
Posts: 1,580
Re: Nighttime Fasting Decreases Breast Cancer Risk

Thanks for this, Fern. Totally believe diet, sugar and eating habits influence cancer's ability to thrive.
Speak soon,
Karen
__________________
World Trade Center Survivor (56th Floor/North Tower): 14 years and still just like yesterday.
Graves Disease, became Euthyroid via Radioactive Iodine, June 2001.
Thyroid Eye Disease. 2003. Decompression surgery in 2009; eyelid lowering surgery in 2010.
Diagnosed: June 2010, liver mets. ER-/PR+10%; HER2+++.
July 2010: Begin Taxol/Herceptin. Eliminate sugar from diet. No surgery or radiation.
January 2011: NED
April 2011: Progression in liver only. Other previous affected areas eradicated. Stop Taxol/Herceptin after 32 infusions.
May 2011: Brain MRI: clear.
May 2011: Begin Tykerb daily, Xeloda twice per day for one week on, one week off, and Herceptin.
November 2011: Progression in liver. All other tumors remain eradicated.
December 2011: BEGIN TRIAL #09-093 Taxol, MCC-DM1 (T-DM1), Perjeta.
Trial requires scans every six weeks, bloodwork and infusions weekly.
Brain MRI: clear.
January 2012: NED. Liver mets, good riddance!
March 2012: NED. Developed SMA (rare blood clot) in intestinal artery and loss of sight in right eye due to optical nerve neuropathy. Resolved when Taxol removed this month.
Continue Protocol of T-DM1 weekly and Perjeta every 3 weeks.
May 2012: NED.
June 2012: Brain MRI: clear.
June-December 2012: NED.
December 2012: TRIAL CONCLUDED; ENTER TRIAL EXTENSION #09-037. CT, Brain MRI, bone scan: clear. NED.
January-March 2013: NED.
June 2013: Brain MRI: clear. CEA upticking; CT shows new met on liver.
July 3, 2013: DISASTER STRIKES during liver ablation: sloppy surgeon cuts intercostal artery and I bleed out, lose 3.5 liters of blood, have major hemothorax, and collapsed lung requiring emergency resuscitative thoracotomy, lung surgery, rib rearrangement and cutting deep connective tissue, transfusion. Ablation incomplete. This life-saving procedure would end up causing me unforgiving pain with every movement I make, permanently, otherwise known as forever.
July 26, 2013: Try Navelbine/Herceptin. Body too weak after surgery and transfusion. Fever. CEA: Normal.
August 16, 2016: second dose Navelbine/Herceptin; CEA: Normal. Will skip doses. Watching and waiting.
September 2013: NED, Herceptin only. CEA: Normal. Started Arimidex.
October-November 2013: NED. Herceptin and Arimidex. CEA, CA125, 15-3: Normal.
December 2013: Something brewing. PET lights up on little spot on liver; CEA upward trend, just outside normal. PET and triphasic liver scan confirm Little Met. Restart Perjeta with Herceptin, stay on Arimidex. Genomic sequencing completed for future treatments, if necessary.
January 2014: Ablate Little Met on the 6th. Happy New Year.
March 2014: Brain MRI: clear. PET/CT reveal liver mets return; new lung mets. This is not funny.
March 2014: BEGIN TRIAL #10-005 A(11)-Temsirolimus plus Neratinib.
April 2014: Genomic testing indicated they could work, they did not. Very strange drug combo for me, felt weird.
April 2014: Started Navelbine and Herceptin. Needed something tried and true, but had significant progression.
June 2014: Doxil and Herceptin.
July 2014: Progression. Got nothing out of it. Brain: NED.
July 2014: Add integrative medical hematologist-oncologist to my team. Begin supplements. These are tumor-busting, immune system boosters. Add glutathione, lysine and taurine IV infusions every three weeks.
July 2014: Begin Gemzar, Herceptin & Perjeta. Happy.
August 2014: ECHO perfect.
January 2015: Begin weekly Vitamin D Analog infusions. 25 mcg. via port.
February 2015: CT: stable.
April 2015: Gem working, but not 100%. Looking into immunotherapy. Finally, treatments for the 21st century!
April 2015: Penn Medicine. Dendritic cell immunotherapy.
KDR is offline   Reply With Quote
Reply


Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off

Forum Jump


All times are GMT -7. The time now is 05:44 PM.


Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021
free webpage hit counter